Monitor for follow-up active manager participation, if active funds begin buying, this could confirm a broader shift in sentiment. Also watch for trading volume and float concentration changes that could drive price momentum.
CGON drugs
CGON drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 2 $57.76entry
- T+1 · 9mo ago +4.83%α +5.75% · $60.55
- T+5 · 8mo ago +6.11%α +7.32% · $61.29
- T+20 · 8mo ago +10.73%α +18.67% · $63.96
- T+60 · 6mo ago +7.15%α −2.18% · $61.89
How similar events traded
Executive Summary
Three major passive institutions, Morgan Stanley, Wells Fargo, and UBS, significantly increased their positions in CG Oncology (CGON) during Q4 2024, collectively adding $37.8M in new exposure with UBS driving the largest increase. This coordinated accumulation by mega-passive funds suggests strong institutional interest, potentially driven by index inclusion or sector reallocation. Despite the bullish cluster, the activity is concentrated in passive managers, which may reflect mechanical rebalancing rather than active conviction.
Key Financial Metrics
Institutional Positions
Net institutional flow: $37.8M
▲ Buyers (3)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| Morgan Stanley | DOUBLED | +208.8% | $20.8M | $11.9M |
| Wells Fargo | ADD | +45.3% | $810.0K | $77.0K |
| UBS | DOUBLED | +1071.7% | $29.1M | $25.8M |
Key Facts
- Morgan Stanley doubled its position, increasing value by $11.9M to $20.8M
- UBS increased its stake by over 1000%, adding $25.8M in value to reach $29.1M
- Wells Fargo added $77K in value, increasing holdings by 45.3%
- No institutional selling was detected in this quarter
Financial Impact
3 institutions accumulated $37.8M in net new positions, bringing total current holdings to $50.7M
Risk Factors
- Activity dominated by passive investors, suggesting rebalancing rather than fundamental conviction
- Lack of active manager participation may limit upside catalyst potential
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-CGON-2024-Q4 |
Track record
25 reports on CGON
5 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +26.33% at T+20 after the Jun 12, 2026 report. 7 of 7 went positive at some point.
Filters
- Nov 16, 2026today 8-K Bullish 7/10 Entry $98.84 settles Dec 15
- Nov 16, 2026today Press Release Bullish 7/10 Entry $95.01 settles Dec 15
- Nov 6, 202610d ago 8-K Bearish 5/10 Entry $75.99 settles Dec 7
- Nov 6, 202610d ago Press Release Neutral 4/10 Entry $75.99 settles Dec 7
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $64.06 settles Dec 2
- Oct 19, 202628d ago 3 Neutral 2/10 Entry $61.93 settles Nov 17
- Oct 15, 20264w ago 144 Neutral 2/10 Entry $59.85 to $74.40 ▲ +24.31% +25.47% vs SPY
- Oct 12, 20265w ago Institutional Cluster Mixed 3/10 Entry $63.13 to $74.74 ▲ +18.39% +21.66% vs SPY
- Aug 6, 202614w ago Press Release Bearish 7/10 Entry $74.85 to $74.33 ▲ +0.69% +1.29% vs SPY
- Aug 6, 202614w ago 424B5 Bearish 6/10 Entry $74.85 to $74.33 ▲ +0.69% +1.29% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers